<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Peripartum <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> is idiopathic <z:hpo ids='HP_0001635'>heart failure</z:hpo> occurring in the absence of any determinable <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> during the last month of pregnancy or the first 5 months postpartum </plain></SENT>
<SENT sid="1" pm="."><plain>The incidence varies worldwide but is high in developing nations; the cause of the disease might be a combination of environmental and genetic factors </plain></SENT>
<SENT sid="2" pm="."><plain>Diagnostic echocardiographic criteria include left ventricular ejection fraction &lt;0.45 or M-mode fractional shortening &lt;30% (or both) and end-diastolic dimension &gt;2.7 cm/m(2) </plain></SENT>
<SENT sid="3" pm="."><plain>Electrocardiography, magnetic resonance imaging, endomyocardial biopsy, and cardiac catheterization aid in the diagnosis and management of peripartum <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Cardiac protein assays can also be useful, as suggested by reports of high levels of NT-proBNP, cardiac troponin, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-α, interleukin-6, interferon-γ, and C-reactive protein in peripartum <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The prevalence of mutations associated with familial <z:hpo ids='HP_0001644'>dilated-cardiomyopathy</z:hpo> genes in patients with peripartum <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> suggests an overlap in the clinical spectrum of these 2 diseases.Treatment for peripartum <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> includes conventional pharmacologic <z:hpo ids='HP_0001635'>heart-failure</z:hpo> therapies-principally <z:chebi fb="40" ids="35498">diuretics</z:chebi>, <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitors</z:chebi>, <z:chebi fb="1" ids="35620">vasodilators</z:chebi>, digoxin, β-blockers, <z:chebi fb="2" ids="50249">anticoagulants</z:chebi>, and peripartum <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>-targeted therapies </plain></SENT>
<SENT sid="6" pm="."><plain>Therapeutic decisions are influenced by drug-safety profiles during pregnancy and lactation </plain></SENT>
<SENT sid="7" pm="."><plain>Mechanical support and transplantation might be necessary in severe cases </plain></SENT>
<SENT sid="8" pm="."><plain>Targeted therapies (such as intravenous immunoglobulin, pentoxifylline, and <z:chebi fb="0" ids="3181">bromocriptine</z:chebi>) have shown promise in small trials but require further evaluation </plain></SENT>
<SENT sid="9" pm="."><plain>Fortunately, despite a mortality rate of up to 10% and a high risk of relapse in subsequent pregnancies, many patients with peripartum <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> recover within 3 to 6 months of disease <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
</text></document>